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The aberrant activity of CD4+ T cells in patients with systemic lupus erythematosus (SLE) is associated with DNA hypomethylation
of the regulatory regions in CD11a and CD70 genes. Our previous studies demonstrated that Gadd45a contributes to the
development of SLE by promoting DNA demethylation in CD4+ T cells. In this study, we identified proteins that bind to Gadd45a
in CD4+ T cells during SLE flare by using the method of co-immunoprecipitation andmass spectrometry, Highmobility group box
protein 1 (HMGB1) is one of identified proteins. Furthermore, gene and protein expression of HMGB1 was significantly increased
in SLE CD4+ T cells compared to controls, andHMGB1mRNAwas correlated with CD11a and CD70mRNA. A significant, positive
correlation was found betweenHMGB1mRNA and SLEDAI for SLE patients. Our data demonstrate that HMGB1 binds to Gadd45a
and may be involved in DNA demethylation in CD4+ T cells during lupus flare.
1. Introduction
Systemic lupus erythematosus (SLE) is a prototype autoim-
munedisease that affectsmultiple organ systems.The etiology
and pathogenesis of SLE remain to be fully defined. Recent
studies have shown that T-cell DNA demethylation plays an
important role in the pathogenesis of SLE [1]. We previously
demonstrated that inhibition of DNA methylation in T cells
resulted in the demethylation of regulatory sequences and
increased gene expression of CD11a (ITGAL) and CD70
(TNFSF7) [2–4]. Increased expression of these genes results
in T-cell autoreactivity and autoantibody production by
the B lymphocyte lineage. The molecular mechanisms that
mediate gene demethylation in SLE CD4+ T cell are not fully
understood, but it is possible that growth arrest and DNA
damage-inducible gene (Gadd45a/Gadd45) may contribute
since increased expression of Gadd45a gene has been shown
to repress DNA methylation, and factors that induce lupus
flare such as ultraviolet have been shown to promote DNA
demethylation in SLE CD4+ T cells [5–7].
In this study, we identified protein(s) that bind to
Gadd45a, assessed their gene and protein expression and
their associationwithCD11a, CD70mRNA, and lupus disease
activity. HMGB1 was identified as a major protein that bind
to Gadd45a, which may contribute to DNA demethylation.
2. Materials and Methods
2.1. Patients and Control Subjects. Ten SLE patients (28.50 ±
10.23 years of age) were recruited from the outpatient clinics
and inpatient Department of Dermatology at the Second
Xiangya Hospital, Central South University. All patients
fulfilled at least 4 of the SLE classification criteria of the
American College of Rheumatology [8]. Disease activity was
quantified by the SLE Disease Activity Index (SLEDAI) [9],
and the mean SLEDAI score of patients recruited into this
study was 7.20 ± 1.93 (Table 1). Age- and sex-matched healthy
controls (25.80 ± 6.89 years of age) were recruited from the
medical staff at the Second Xiangya Hospital. This study
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Figure 1: Representative gel showing protein bands immunopre-
cipitated with anti-human Gadd45a antibody. Lane 1: prestained
markers, lanes 3, 5, and 7: immunoprecipitated with anti-Gadd45a
antibody, and lanes 2, 4, and 6: immunoprecipitated with isotype-
matched control IgG.
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Figure 2: Real-time PCR quantification of HMGB1 mRNA in
CD4+ T cells. HMGB1 mRNA in CD4+ T cells isolated from
patients with SLE and healthy controls was determined by quantita-
tive real-time PCR. Results are normalized to 𝛽-actin and presented
as mean + SD.
was approved by the human ethics committee of the Second
Xiangya Hospital.
2.2. Isolation of CD4+ T Cells. Peripheral blood mononu-
clear cells were isolated from heparin-anticoagulated whole
blood using Ficoll-Hypaque density gradient centrifugation
(Shanghai Hengxin Chemical Reagent Co., Ltd., Shanghai,
China), and CD4+ T cells were isolated by positive selec-
tion using Miltenyi beads, according to the manufacturer’s
instructions (Miltenyi, Germany). The purity of the enriched
subsets was validated by flow cytometry and was >95%.
Table 1: Patient demographics and treatment.
Patient Age/gender SLEDAI Treatment
1 49/F 12 None
2 38/F 6 Pred 20mg/d
3 23/F 6 None
4 35/F 6 Pred 5mg/d
5 15/F 8 None
6 34/F 6 None
7 24/F 8 None
8 25/F 6 None
9 22/F 8 Pred 30mg + CTX
10 20/F 6 Pred 10mg
F: female; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index;
Pred: Prednisone; CTX: Cyclophosphamide.
2.3. Coimmunoprecipitation and LS-MS/MS. CD4+ T cells
were solubilized with cell lysis buffer (KeyGEN, China).
Aliquots of CD4+ T-cell lysates were incubated overnight
at 4∘C with rabbit anti-human Gadd45a antibody (Santa
Cruz Biotechnology, USA) or isotype-matched rabbit IgG
(Beyotime, China) prior to the absorption with protein A/G
PLUS-agarose beads (Millipore, USA) at 4∘C for 1 hour.
Proteins that bound to Gadd45a were centrifuged and eluted.
Immunoprecipitated samples were incubated with 2 × SDS
electrophoresis sample buffer at 95∘C for 5min and subjected
to SDS-PAGE followed by staining with Coomassie blue.
Bands of interest were excised, and sent to BGI (Shenzhen,
China) for identification using LS-MS.
2.4. Western Blot. Aliquots of CD4+ T-cell proteins were
denatured, separated by SDS-PAGE, and transferred to PVDF
membranes (Amersham Bioscience, GE Healthcare Com-
pany, USA). The membranes were incubated overnight at
4∘C with rabbit anti-human HMGB1 polyclonal antibody
(diluted 1 : 500, Abcam, USA) followed by incubation with
horseradish peroxide-conjugatedmouse anti-rabbit antibody
(diluted 1 : 3000, Santa Cruz, USA). Bands were detected
with Pierce chemiluminescence detection system (Thermo
Scientic, Rockford, IL, USA). All bands were normalized to
𝛽-actin.
2.5. Real-Time Polymerase Chain Reaction. Total RNA was
isolated from CD4+ T cells obtained from healthy controls
and patients with SLE using TRIzol (Invitrogen, USA) and
1 𝜇g total RNA reverse transcribed into cDNA using Rever-
tAid First Strand cDNA Synthesis Kit (Fermentas, Canada).
Quantitative real-time PCRwas performed in duplicate using
SYBRPremix ExTag kit (Takara, Japan) in aRotor-Gene 3000
thermocycler. Primers used included
HMGB1 Forward: 5󸀠-TCACAG CCATTG CAG TACATT
GAG-3󸀠
Reverse: 5󸀠-GGATCT CCT TTG CCC ATG TTT
AGT T-3󸀠
CD70 Forward: 5󸀠-CACACTCTGCACCTCACT-3󸀠
Reverse: 5󸀠-CACCCACTGCACTCCAAAGA-3󸀠
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CD11a Forward: 5󸀠-TGAGAGCAGGCTATTTGGGT
TAC-3󸀠
Reverse: 5󸀠-CGGCCCATGTGCTGGTAT-3󸀠
𝛽-actin Forward: 5󸀠-CGCGAGAAGATGACCCAGAT-3󸀠
Reverse: 5󸀠-GCACTGTGTTGGCGTACAGG-3󸀠
2.6. Statistical Analysis. Results were expressed as mean +
SD. Intergroup analysis was performed using Student’s 𝑡-test.
Correlation ofHMGB1mRNAwithCD11a, CD70mRNAand
SLEDAI was assessed by Pearson’s correlation coefficient. 𝑃
values < 0.05 were considered significant. All analyses were
performed with SPSS version 15.0 software.
3. Results
3.1. Identification of Proteins That Bound to Gadd45a. To
identify proteins that bind to Gadd45a, total proteins
extracted from CD4+ T cell were immunoprecipitated with
anti-human Gadd45a antibodies, separated by SDS-PAGE,
and stained with Coomassie blue. Anti-Gadd45a antibodies
but not isotype-matched control immunoprecipitated two
bands with MW of ∼30 and ∼26 kDa (Figure 1). A protein
band with MW ∼55 kDa was detected by both anti-Gadd45a
antibodies and control IgG. These bands were excised, sub-
jected to in-gel trypsin digestion, and subjected to Tandem
MS. Data obtained were analyzed against the Gene Ontology
annotations to proteins in the UniProt Knowledgebase using
Mascot 2.3.02 software. (Proteins listed in Table 2 are MW of
∼30KDa and∼26KDa proteins precipitated by anti-Gadd45a
antibodies and MW ∼55KDa proteins which are different
proteins between the anti-Gadd45a antibodies precipitation
group and control antibody precipitation group.)
3.2. Gene and Protein Expression of HMGB1 in CD4+ T Cells
fromSLEPatients withActiveDisease. HMGB1was identified
as the protein that bound to Gadd45a by immunoprecipita-
tion. Elevated expression was confirmed in PBMC and serum
in SLE patients in previous studies [10–12]. In addition, it may
interact with various proteins, includingmethy-CpG binding
protein2 (MeCP2) [13]. So we compared HMGB1 mRNA
levels inCD4+ T cells fromSLE patients and healthy controls.
Gene and protein expression of HMGB1 was significantly
increased in SLE CD4+ T cells compared to CD4+ T cells
isolated from healthy subjects (𝑃 = 0.01 and 𝑃 = 0.018, resp.)
(Figures 2, 3(a), and 3(b)).
Gene expression of HMGB1 was significantly correlated
with CD11a and CD70 mRNA in CD4+ T cell (𝑅 = 0.737,
𝑃 = 0.000; 𝑅 = 0.650, 𝑃 = 0.002, resp.) (Figures 4(a)
and 4(b)). Furthermore, we analyzed the correlation between
HMGB1 mRNA and lupus disease activity as measured by
the SLEDAI. A positive correlation was also found between
HMGB1mRNA and SLEDAI (𝑅 = 0.797, 𝑃 = 0.006)
(Figure 5).
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Figure 3: Protein expression of HMGB1 in CD4+ T cells using
western blot. (a) Representative western blot showing protein
expression of HMGB1 in CD4+ T cells isolated from patients with
SLE and healthy controls. (b) Bar chart showing the mean intensity
of the bands as determined by densitometric scan, normalized to the
house-keeping gene, 𝛽-actin.
4. Discussion
Over the past two decades, global DNA hypomethylation
and gene-specific DNA demethylation have been observed
in T cells in patients with idiopathic lupus and drug-induced
lupus. Gadd45a (Gadd45a/Gadd45) is a nuclear protein that
plays an important role in the maintenance of genomic
stability, DNA repair, and suppression of cell growth. In
our previous studies, we have demonstrated that Gadd45a
contributes to autoimmune diseases by promoting DNA
demethylation [5]. In this study, we identified proteins that
bind to Gadd45a in SLE CD4+ T cells that may assist in DNA
demethylation. Using LS-MS/MS, we identified HMGB1 as
one of the proteins that bind to Gadd45a. Gene and protein
expression of HMGB1 was increased in SLE CD4+ T cells
compared to control CD4+ T cells. HMGB1 is a nuclear DNA
binding protein secreted bymonocytes andmacrophages and
plays a critical role in innate immunity, inflammation, and
sterile injury [14]. Serum HMGB1 levels are increased in SLE
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Figure 4: Correlation between HMGB1 mRNA and CD11a and
CD70 mRNA. Gene expression of HMGB1, CD11a, and CD70 was
assessed by real-time PCR. Correlation between HMGB1 mRNA
and (a) CD11a mRNA and (b) CD70 mRNA is shown for CD4+ T
cells in SLE patients and controls.
patients and its expression is increased in skin lesions in lupus
patients [10–12, 15].
HMGB1 interacts with numerous proteins such as
methyl-CpG binding protein-2 (MeCP2), a protein that
participates in the recognition of methylated DNA in CpG
islands [13]. In this study, we demonstrated that gene and
protein expression of HMGB1 in CD4+ T cells is signifi-
cantly increased in SLE patients compared to healthy con-
trols thereby corroborating previous studies. Furthermore,
HMGB1 mRNA in CD4+ T cells is correlated with SLEDAI
for SLE patients. Given that CD4+ T cells promote inflamma-
tion and autoimmunity, it is plausible to suggest that HMGB1
contributes to the pathogenesis of SLE [16].
CD11a plays a key role in cellular adhesion and cos-
timulatory signaling. Its expression is increased in T cells
consequent to hypomethylation and correlateswith the devel-
opment of T-cell autoreactivity in SLE patients [3, 4]. CD70 is
amethylation-sensitive gene present in T cells. Costimulatory
signals mediated through CD70-CD27 interactions regulate
Table 2: Proteins identified by LS-MS/MS.
Protein mass Description
∼26KDa, ∼30KDa
25049.23 HMGB1 High mobility group protein B1
29807.14 RPS4X 40S (ribosomal protein S4, X isoform)
27898.79 YWHAZ 14-3-3 protein zeta/delta
14126.95
HIST1H2AB; HIST1H2AE; HIST1H2AD;
HIST1H2AG; HIST1H2AK; HIST1H2AI;
HIST1H2AL; HIST1H2AM; HIST1H2AJ
Histone H2A type 1-B/E
38837.09 HNRNPA1 Isoform A1-B of Heterogeneousnuclear ribonucleoprotein A1
28876.08 PSME1 Proteasome activator complex subunit 1
32179.71 HNRNPCL1 Heterogeneous nuclearribonucleoprotein C-like 1
36201.46 GAPDH Glyceraldehyde-3-phosphatedehydrogenase
18885.87 RPS10 40S ribosomal protein S10
33059.24 SLC25A5 ADP/ATP translocase 2
37463.75 HNRNPA2B1 Isoform B1 of Heterogeneousnuclear ribonucleoproteins A2/B1
15215.62 PFN1 Profilin-1
25119.3 IGLC2; IGLV2-14 IGL@ protein
24820.32 RAB27B Ras-related protein Rab-27B
22449.98 DRAP1 Isoform 1 of Dr1-associated corepressor
32867.15 TNFAIP8L3 Tumor necrosis factoralpha-induced protein 8-like protein 3
16982.46 LYZ Lysozyme C
31881.8 STOM Erythrocyte band 7 integral membraneprotein
24764.75 SNRPB Isoform SM-B
󸀠 of Small nuclear
ribonucleoprotein-associated proteins B and B󸀠
19545.99 SRSF3 Serine/arginine-rich splicing factor 3
17707.86 RPS18 40S ribosomal protein S18
38805.89 ANXA2P2 Putative annexin A2-like protein
26688.86 AK2 Isoform 1 of Adenylate kinase 2,mitochondrial
21950.62 IMP3 U3 small nucleolar ribonucleoproteinprotein IMP3
22113.26 RPS7 40S ribosomal protein S7
30729.42 ASB13 Isoform 1 of Ankyrin repeat and SOCSbox protein 13
∼55KDa
52076.78 PPP2R2B Isoform 1 ofSerine/threonine-protein phosphatase 2A 55
52324.86 CAP1 Isoform 1 of Adenylyl cyclase-associatedprotein 1
56456.49 EEF1G cDNA FLJ56389, highly similar toElongation factor 1-gamma
52586.54 EIF3E Eukaryotic translation initiation factor 3subunit E
B-cell activation and autoantibody production, thereby high-
lighting the role of CD70 in the pathogenesis of SLE. In this
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Figure 5: Correlation between HMGB1mRNA and SLEDAI. Lupus
disease activity was quantified by the SLE Disease Activity Index
(SLEDAI). Correlation between HMGB1 mRNA in lupus CD4+ T
cells and SLEDAI for lupus patients is shown.
study, we demonstrated that HMGB1 mRNA is significantly
correlated with CD11a and CD70 mRNA.
In conclusion, we have demonstrated that HMGB1 binds
to Gadd45a and its increased gene expression which is
associated with a concomitant increase in CD11a and CD70
mRNA may be involved in DNA demethylation in CD4+ T
cells, thus contributing to the pathogenesis of SLE. Further
studies are currently ongoing to delineate the function of
HMGB1 and its underlying mechanism contributing to DNA
demethylation in CD4+ T cells during pathogenesis of SLE.
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